breast-cancer

Protein FILIP1L acts as a metastasis coordinator in breast cancer, linking cell division timing to invasive behavior

Cancer cells invade surrounding tissue using specialized structures called invadopodia — spiky protrusions armed with enzymes that chew through the extracellular matrix. Researchers discovered that when breast cancer cells undergo epithelial-to-mesenchymal transition (EMT, the process that makes cancer cells more invasive), the timing of invadopodia activity shifts across different phases of the cell cycle.

At the center of this shift is a previously overlooked protein called FILIP1L. Its expression tracks with whichever cell cycle phase is most invasive for a given EMT state — and losing FILIP1L increases local matrix destruction but paradoxically reduces the cell's ability to migrate and invade in 3D. In mouse models, tumors with FILIP1L knocked down formed fewer metastatic colonies.

In human breast cancer patients, high FILIP1L expression correlated with more advanced EMT and worse outcomes — suggesting it's a marker of invasive disease and a potential therapeutic target.

Key Findings

Invadopodia activity shifts from G2 phase (early EMT) to G1 phase (late EMT) as cancer cells become more invasive
FILIP1L is a novel invadopodia component whose expression peaks during the most invasive cell cycle phase of each EMT state
FILIP1L loss increases ECM degradation locally but impairs migration and 3D invasion
FILIP1L knockdown in mouse models resulted in fewer metastatic colonies
High FILIP1L expression correlates with EMT progression and poor outcomes in breast cancer patients

Implications

FILIP1L is a newly identified link between the cell cycle, EMT, and metastatic invasion. It may serve as a prognostic biomarker in breast cancer and, given its role coordinating invasion, a therapeutic target to prevent metastasis. Understanding how cell cycle phase gates invasive behavior could open new windows for anti-metastatic treatment timing.

Caveats

Preprint — not peer reviewed. Mouse model metastasis data and cell line experiments need independent validation. The correlation with poor patient outcomes is associative, not causal. Therapeutic targeting of FILIP1L is speculative at this stage.

Source: bioRxiv — 2026-04-07

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.